Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

March 7, 2019

Patients with ACE Inhibitor-induced Swelling May Safely Switch to AT2 Blockers, Study Suggests

News

Patients who experience an angioedema attack during treatment with angiotensin-converting enzyme inhibitors — a kind of medication for high blood pressure and heart failure — may safely switch to a ... Read more

December 6, 2018

Takhzyro Approved in Europe for Routine Prevention of Hereditary Angioedema Attacks

News

Takhzyro (lanadelumab), a kallikrein inhibitor by Shire, has been approved in Europe for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, making it the first antibody available in ... Read more

December 4, 2018

Takhzyro Significantly Reduces Rate of Hereditary Angioedema Attacks, Phase 3 Trial Shows

News

Routine treatment with Shire‘s Takhzyro (lanadelumab) — given as a 300 mg dose every two weeks — significantly reduces the rate of acute attacks in hereditary angioedema (HAE) patients age 12 ... Read more

June 28, 2018

FDA Approves Shire’s Cinryze for Preventing Pediatric Angioedema Attacks

News

The U.S. Food and Drug Administration recently approved Shire’s Cinryze (C1 esterase inhibitor ) to help prevent angioedema attacks in children 6 and older who live with hereditary angioedema (HAE). ... Read more

May 29, 2018

European Agency Issues Positive Opinion on Orphan Drug Status for BXC7353 to Treat HAE

News

The European Medicines Agency issued a positive opinion on BioCryst Pharmaceuticals’ application for orphan drug status of BCX7353 to treat hereditary angioedema (HAE). The European Commission is expected to adopt the ... Read more

April 26, 2018

Swiss Agency to Begin Review Process for Lanadelumab to Treat Hereditary Angioedema

News

A marketing authorization application for Lanadelumab, Shire‘s investigational therapy for hereditary angioedema (HAE), was recently cleared by the Swiss Agency for Therapeutic Products (Swissmedic), the company announced. Supported by data from ... Read more

March 13, 2018March 13, 2018

FDA to Give Priority Review to Hereditary Angioedema Therapy Lanadelumab

News

The U.S. Food and Drug Administration plans a priority review of lanadelumab, Shire’s kallikrein inhibitor to prevent hereditary angioedema swelling attacks. Shire is asking for the therapy’s approval for patients aged ... Read more

February 27, 2018February 27, 2018

FDA Will Review Cinryze as Preventative for Pediatric Hereditary Angioedema Patients

News

The U.S. Food and Drug Administration (FDA) will review Shire’s application requesting that Cinryze (C1 esterase inhibitor ) be approved for the prevention of hereditary angioedema attacks in children 6 years and older. ... Read more

February 20, 2018February 20, 2018

Health Canada Grants Priority Review of Lanadelumab as Prevention for Angioedema Attacks

News

The application requesting that lanadelumab be reviewed with priority as a new treatment for the prevention of angioedema attacks has been accepted by Health Canada, the medicine’s manufacturer, Shire, announced. The New Drug ... Read more

February 6, 2018February 6, 2018

BioCryst and Idera Merger Aims to Serve More Patients with Rare Diseases, Companies Say

News

The recently announced merger of BioCryst Pharmaceuticals and Idera Pharmaceuticals will strengthen the two companies’ focus on developing and commercializing treatments to serve patients with rare diseases, including angioedema, the companies ... Read more

Pin It on Pinterest